双歧杆菌及其WPG对S180荷瘤小鼠免疫调节和抑瘤的作用研究

目的 通过观察双歧杆菌及其细胞壁肽多糖（Cell Wall Preparation,whole peptidoglycon,WPG)对S180荷瘤小鼠抑瘤作用及在体内外对IL－6和TNF－α生态的影响,探讨双歧杆菌及其WOG的免疫调节和抑瘤作用机制。方法 采用经驯化而具有一定耐氧能力的两歧双歧杆菌C149株及其WPG腹腔免疫S180荷瘤小鼠,应用放射免疫检测小鼠外周血中的IL－6和TNF－α的含量,同时在体外观察小鼠腹腔巨噬细胞产生IL－6和TNF－α的影响。结果 双歧杆菌及其WPG在体内外对IL－6和TNF－α的生成有明显的促进作用,对S180荷瘤小鼠均有明显抑瘤作用。结论 双歧杆菌及其WPG可能通过刺激小鼠的巨噬细胞产生一些免疫活性因子而间接发挥抑瘤作用。     

短小双歧杆菌对机体几种重要细胞因子诱生作用研究

本实验观察了热杀的短小双歧杆菌对小鼠ＴＮＦ—α、ＩＬ—１、ＩＬ—２等细胞因子的诱生活性的影响。结果表明,短小双歧杆菌腹腔注射后,小鼠ＴＮＦ—α、ＩＬ—１、ＩＬ—２诱生活性显著增强,本文结果提示,短小双歧杆菌可能通过其细胞壁免疫活性成分而发挥免疫调节作用。     

双歧杆菌的完整肽聚糖对实验性大肠癌凋亡控制基因表达的影响

为探讨双歧杆菌的完整肽聚糖的抑瘤途径及机制,本文以大肠癌裸鼠移植瘤为动物模型,采用免疫组化ＳＰ法检测了４０只裸鼠移植瘤ｂｃｌ－２及ｂａｘ基因的蛋白表达率及表达强度,结果显示肽聚糖注射组大肠癌移植瘤ｂｃｌ－２蛋白表达率及阳性细胞密度低于肿瘤对照组,ｂｃｘ基因的表达情况则相反。提示双歧杆菌的完整肽聚糖可使大肠癌裸鼠移植瘤的ｂｃｌ－２基因表达下调,ｂａｘ基因表达强,最终诱导肿瘤细胞凋亡,实现其抗瘤目的。     

双歧杆菌的完整肽聚糖对实验性大肠癌凋亡调控基因表达的影响

为探讨双歧杆菌的完整肽聚糖的抑瘤途径及机制,本文以大肠癌裸鼠移植瘤为动物模型,采用免疫组化ＳＰ法检测了４０只裸鼠移植瘤ｂｃｌ－２及ｂａｘ基因的蛋白表达率及表达强度。结果显示完整肽聚糖注射组大肠癌移植瘤ｂｃｌ－２蛋白表达率及阳性细胞密度均低于肿瘤对照组,ｂａｘ基因的表达情况则相反。提示双歧杆菌的完整肽聚糖可使大肠癌裸鼠移植瘤的ｂｃｌ－２基因表达下调,ｂａｘ基因表达增强,最终诱导肿瘤细胞凋亡,实现其抗瘤目的。     

双歧杆菌总DNA对小鼠IL—2,NK活性影响的研究

目的 从双歧杆菌、大肠杆菌提取ＤＮＡ,用ＤＮＡ免疫小鼠,观察免疫功能的变化,探讨双歧杆菌ＤＮＡ对小鼠免疫功能的影响,并作对比研究。方法 肌肉注射提取的双歧杆菌ＤＮＡ、大肠杆菌ＤＮＡ,颈椎处死后,检测脾细胞的免疫功能,同时提取ＩＥＬ细胞与ＤＮＡ共孵育,检测它对ＩＥＬ细胞的激活情况及细胞因子产生情况,以自然杀伤细胞（ＮＫ）活性,白细胞介素２（ＩＬ－２）产生能力为指标,测定小鼠上述各项指标变化。结果 双歧杆菌ＤＮＡ、大肠杆菌ＤＮＡ肌肉注射后,小鼠以上两项指标与相应对照组相比较均明显提高（Ｐ〈０．０５）。双歧杆菌ＤＮＡ提高小鼠ＮＫ活性与ＩＬ－２水平程度大于大肠杆菌ＤＮＡ的作用（Ｐ〈０．０１）。结论 双歧杆菌ＤＮＡ可快速激活ＮＫ活性,提高体内ＩＬ－２水平。其效能优于大肠杆菌ＤＮＡ。     

双歧杆菌及其表面分子的免疫增强作用

研究双歧杆菌及其脂磷壁酸、细胞壁肽聚糖、培养乏液对小鼠腹腔渗出细胞、脾细胞ＩＬ－１、ＩＬ－２、ＩＬ－６、ＴＮＦ、ＩＦＮ－γ活性和脾ＮＫ、ＬＡＫ细胞活性的影响。结果发现双歧杆菌全菌、脂磷壁酸、肽聚糖多次注入小鼠腹腔一段时间后,小鼠脾ＮＫ细胞、ＬＡＫ细胞活性和ＩＦＮ－γ活性增强,腹腔渗出细胞产生ＩＬ－１、ＩＬ－６、ＴＮＦ活性增强,其中以脂磷壁酸作用最强,肽聚糖次之,培养乏液也有一定作用。双歧杆菌及其表面分子对小鼠脾细胞、腹腔渗出细胞ＩＬ－２活性无显著影响。双歧杆菌的免疫增强作用在抗感染、抗肿瘤机理中占有十分重要的地位。     

大肠杆菌-长双歧杆菌穿梭载体的构建及PTEN在长双歧杆菌中的表达

长双歧杆菌可特异地定植于实体瘤低氧区,可用做肿瘤靶向性基因治疗的载体,而构建大肠杆菌-长双歧杆菌穿梭质粒则被证明是外源基因在长双歧杆菌中稳定表达的有效途径。为了构建能在长双歧杆菌中稳定表达外源基因的穿梭质粒并检测携带抑癌基因的工程菌对小鼠实体瘤的抑制效果,利用软件设计并合成了48条部分序列相互重叠的引物,通过PCR合成了长双歧杆菌质粒pMB1序列及长双歧杆菌HU启动子区序列,插入克隆载体pMD18-T,构建穿梭载体pMB-HU,该载体可在大肠杆菌DH5α及长双歧杆菌L17中稳定复制。PTEN基因编码具有蛋白质和酯类双重特异性磷酸酶活性的抑癌因子。将PTEN基因cDNA序列插入载体pMB-HU中HU启动子下游,构建重组质粒pMB-HU-PTEN,电击转化长双歧杆菌后,Western blot检测表明,表达产物中存在55kDa的PTEN蛋白特异条带。抑癌试验表明:与对照组相比,携带PTEN基因的长双歧杆菌可显著抑制小鼠实体瘤的生长。上述结果为以长双歧杆菌为载体的实体瘤靶向性基因治疗研究奠定了基础。     

LC—CW的抗肿瘤作用及其机理的研究

提取干酪乳酸杆菌细胞壁成分,研究其抗肿瘤作用及其机理。结果表明：１００μｇ－ＬＣ－ＣＷ,ｉｐ,连续４天,可明显抑制小鼠Ｓ１８０腹水瘤移植物的生长,抑瘤率为５４％。增强ＩＬ－２诱导的ＬＡＫ杀伤活性。可明显促进小鼠ＮＫ杀伤活性,明显促进小鼠Ｔ细胞转化,促进ＣｏｎＡ和ＰＨＡ－Ｐ诱导的ＩＬ－２产生,促进ＳＩＬ－２Ｒ的减少。     

蕲蛇酶抗小鼠实验性肿瘤转移作用研究

目的：探讨从尖吻蝮蛇毒中分离得到的具有凝血酶样酶活性的蕲蛇酶抗实验性肿瘤转移作用。方法：用尾静脉注射体外培养的黑色素瘤Ｂ１６和肉瘤Ｓ－１８０细胞的小鼠肺转移模型,注射瘤细胞前后分别腹腔注射药物,２０天后处死小鼠,计数肺表面转移瘤结节数。结果蕲蛇酶剂量在２－５ＡＵ／ｋｇｉｐ能明显减少Ｂ１６在Ｃ５７ＢＬ小鼠及Ｓ－１８０在昆明鼠的肺转移结节数,但对转移瘤小鼠的生命无明显的延长作用。结论蕲蛇酶具有抗小鼠实     

双歧杆菌对裸鼠腹腔巨噬细胞产生IL—1及IL—6的影响

给裸小鼠腹腔注射活的青春型双歧杆菌,并以小鼠胸腺细胞增殖法及ＥＬＩＳＡ法分别检测了裸鼠腹腔巨噬细胞分泌的ＩＬ１活性及ＩＬ６含量。结果表明：实验组裸鼠腹腔巨噬细胞分泌的ＩＬ１活性以及ＩＬ６含量均显著高于对照组,两者均具有统计学意义（ｐ＜００１）。这提示青春型双歧杆菌可激活巨噬细胞产生ＩＬ１以及ＩＬ６,它们在该菌调节机体免疫反应中可能起一定作用。     

The promotive effect of interleukin 4 with interleukin 2 in the proliferation of tumor-infiltrating lymphocytes from patients with malignant tumor

In adoptive immunotherapy, the number of effector cells is one of the major factors relating to the therapeutic efficacy. We demonstrated that tumor-infiltrating lymphocytes (TILs) were stimulated to proliferate by incubation with interleukin 2 (IL-2) plus interleukin 4 (IL-4). TILs cultured with IL-2 plus IL-4 increased 3.1-fold more than TILs cultured with IL-2 alone. However, IL-4 did not alter the cytotoxic activity of TILs against autologous tumor cells and established tumor cell lines. It is suggested that IL-2 receptor is related to the mechanism of the proliferation of activated TILs cultured by combination with IL-2 and IL-4. Thus, the combination of IL-2 and IL-4 may increase the efficacy of adoptive immunotherapy using activated TILs.     

Characterization of IL-2-activated TILs and their use in intrapericardial immunotherapy in malignant pericardial effusion

Pericardial effusion (PE) and cardiac tamponade caused by malignant pericarditis are critical conditions in cancer patients, which still lack a recommended protocol for their long-term management. Percutaneous pericardiocentesis and simple drainage are commonly performed as the initial treatment. The aims of this study were to investigate the presence of cytotoxic T lymphocytes (CTLs) in malignant PE and to determine the clinical response to administering autologous tumor-infiltrating lymphocytes (TILs) into the pericardial cavity. Initially, we identified human lymphocyte antigen class-I-restricted and tumor-specific CTLs within the interleukin-2 (IL-2)-activated TILs in PEs from four patients, on the basis of interferon-γ production and lactate dehydrogenase-release assays. Clinically we observed favorable responses to the pericardial transfer of IL-2-activated autologous TILs in four patients: one male with advanced esophageal cancer, one female with recurrent lung cancer and two females with recurrent breast cancer, respectively. Autologous TILs from PEs were expanded in vitro with IL-2, characterized for CD3, CD4 and CD8 markers, checked for contamination and then infused into the patient’s pericardial space through a catheter. This was repeated biweekly. After treatment, there were no signs of recurrence of PE in either case, as determined by radiography, echocardiography and computed tomography. The only adverse effects seen were grade 1 fevers. These results suggested that intrapericardial cellular immunotherapy with autologous TILs could be a safe and effective treatment for controlling malignant pericarditis with associated cardiac tamponade, and that tumor-specific CTLs present in malignant PE might be important for tumor rejection.     

Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody

Summary Heteroconjugate (HC) antibody (anti-CD3 mAb × anti-p97 melanoma mAb) or monomeric anti-CD3 mAb by itself did not induce proliferation of uncultured melanoma tumor-infiltrating lymphocytes (TILs). They also failed to induce IL-2 production in uncultured TILs, although anti-CD3 mAb, but not HC antibody, stimulated IL-2 production in peripheral blood mononuclear cells (PBMCs). Sequential treatment of uncultured TILs from p97-antigen-positive (p97⁺) melanomas with HC antibody, followed by washing and incubation with interleukin-2 (IL-2), induced significantly higher proliferation than incubation with IL-2 alone. HC antibody pretreatment led to significantly greater results than with anti-CD3 mAb at a 1 ng/ml level in IL-2-induced proliferation of TILs from p97⁺ melanomas, similar to those with anti-CD3 mAb at a level of 100 ng/ml. HC antibody (1 ng/ml) pretretment did not enhance IL-2-induced proliferation of either TILs from p97^– melanomas or PBMCs, while anti-CD3 mAb enhanced the proliferation of TILs from some p97^– melanomas and PBMCs. Regardless of the pretreatment of uncultured TILs with HC antibody or anti-CD3 mAb, IL-2-activated TILs were cytotoxic primarily only to autologous tumor cells, and their phenotypes remained the same. Thus, HC antibody can augment IL-2-induced activation of TILs only from p97⁺ melanomas, without altering their pattern of cytotoxicity or phenotype. The findings were consistent with observations at the clonal level. In contrast to anti-CD3 mAb, HC pretreatment of uncultured TILs from only p97⁺ melanoma prior to limiting-dilution analysis increased the number of proliferating TIL clones, including autologous tumor-specific cytotoxic T lymphocyte clones. These results suggest that use of HC antibody in vivo would be more advantageous than anti-CD3 mAb, with regard to augmentation of IL-2-induced TIL activation.This work was supported in part by grants CA47 891, CA09 599, and RR5511-27 from the National Institutes of Health     

Autologous tumor cell killing activity of tumor-associated lymphocytes in patients with head and neck carcinomas

In order to select the most cytotoxic effector cells for adoptive immunotherapy, lymphokine activated killer (LAK) cells, tumor infiltrating lymphocytes (TILs) and autologous mixed lymphocyte tumor cell culture (MLTC) cells derived from peripheral blood mononuclear cells (PBMC) in the same subject with head and neck carcinomas were prepared. The autologous tumor cell killing activity and cell surface phenotypes of each of the three effector cells were studied. MLTC cells cultured with interleukin-2 (IL-2) showed the strongest cytotoxic activity among these three different effector cells. Although TILs had suppressed killing activity immediately after isolation, after successive cultivations with IL-2, a cytotoxic activity against autologous tumor cells stronger than that of LAK cells appeared. Both IL-2 stimulated MLTC cells and TILs showed an enrichment of CD8 positive and CDU negative cells in a CD3 positive subpopulation.Abbreviations CD cluster differentiation - IL-2 interleukin-2 - LA lymphokine activated - LAK lymphokine activated killer - MLTC mixed lymphocyte tumor cell culture - NK natural killer - PBMC peripheral blood mononuclear cells - TILs tumor infiltrating lymphocytes     

The synergistic effects of interleukin 2 and interleukin 7 on the proliferation and autologous tumor cell lysis of tumor-associated lymphocytes

Interleukin-7 (IL-7) has an ability to stimulate the proliferation of pre-B cells. It has been shown that IL-7 can also activate T lymphocytes. We here demonstrate that IL-7 in combination with interleukin-2 (IL-2) can drive cell proliferation and enhance the autologous tumor cell lysis by peripheral blood mononuclear cells (PBMC) and autologous mixed lymphocyte tumor cell culture (MLTC)-derived effector cells (MLTC cells). These synergistic effects of IL-2 and IL-7 on the proliferation and the augmentation of autologous tumor cell lysis were found for both effector cells. These effects were inhibited by neutralizing antibodies to IL-2 or IL-7, and by a combination of both antibodies, significantly. In terms of phenotypical expression, CD3 positive cells comprised the vast majority of MLTC cells after culture in medium containing IL-2 and IL-7 with an increase of IL-2 receptor positive cells.Abbreviations CD cluster differentiation - IFN interferon - IL interleukin - JRU Japanese Reference Unit - LAK lymphokine activated killer - mAb monoclonal antibody - MLTC mixed lymphocyte tumor cell culture - PBMC peripheral blood mononuclear cells - TILs tumor infiltrating lymphocytes     

Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy

Summary Alteration in interactions between tumor-infiltrating lymphocytes (TILs) and tumor cells after chemotherapy or immunotherapy was studied in metastatic melanoma patients. Tumors were harvested from surgical specimens 17 days after the end of chemotherapy with cisplatin, vinblastine, and dacarbazine (CVD). Tumors of nonlymph-node metastases from two responders yielded neither TILs nor tumor cells, whereas those from all four nonresponders had both TILs [(1.1–13.8) × 10⁶ cells/g tumor] and tumor cells [(2.8–30.8) × 10⁶ cells/g tumor). Tumors of lymph node metastases from nine patients yielded substantial numbers both of TILs and tumor cells, regardless of different clinical responses, except with one complete responder, whose tumor did not contain tumor cells. The mean increase of TILs from these tumors (n = 14) 3–4 weeks after incubation with 200 U/ml recombinant interleukin-2 (rIL-2) was 2.5-fold, whereas there was a 56-fold increase in TILs from untreated tumors (n = 3). CD3⁺ T cells predominated in TILs before and after expansion with IL-2. IL-2-activated TILs from five of six tumors tested displayed higher cytotoxicity against autologous tumor cells than against cells from any of three allogeneic tumors. Mean tumor cell numbers (10⁶ cells/trial) obtained by serial needle biopsies for the same tumor in five patients decreased from 1.2 before therapy to 0.25 at day 4 of therapy (interferon alone), and to 0.02 at day 8 (interferon and IL-2). This decrease did not correlate with clinical responses. Yields (× 10⁶ cells/g tumor) of TILs and tumor cells in subcutaneous melanomas obtained by excisional biopsies in one nonresponder under IL-2 therapy were respectively 0.2 and 1.1 before therapy (day 0), 0.1 and <0.01 during (day 7), 0.2 and <0.01 at the end of therapy (day 21), and 0.5 and 0.5 at the time of tumor progression (day 66). Yields of TILs and tumor cells in the other nonresponder were respectively 3 and 26 before (day 0), 16 and 3 during (day 7), and 0.4 and <0.01 at the end of IL-2 therapy (day 17), and 2.5 and 6 at the time of progression (day 62). TILs in these two patients before therapy proliferated well in culture with IL-2 (570-and 720-fold, respectively), and showed higher cytotoxicity against autologous tumor cells, whereas none of those from the five tumors biopsied during or at the end of IL-2 therapy proliferated. TILs at the time of progression showed modest proliferation (54- and 76-fold, respectively) and showed major-histocompatibility-complexnonrestricted cytotoxicity. In summary, a decrease in the number of live tumor cells did not always correlate with clinical response in either therapy. CVD chemotherapy may simply impair IL-2-induced proliferation of TILs. IL-2 therapy may induce transient unresponsiveness of TILs to IL-2.This work was supported in part by grant CA 47 891 from the National Institutes of Health and a grant from the University Cancer Foundation, and Mr Richard Hunton Melanoma Found.     

Functional and phenotypic analyses of interleukin 2-activated tumor-infiltrating lymphocytes

The tumor-infiltrating lymphocytes (TILs) were cultured with interleukin 2 (IL-2) to induce the activated killer cells possessing autologous tumor-killing activity, and analysed their cell surface phenotypes and assessed anti-tumor killing activity. Furthermore, the activated TILs were transferred into 7 patients adoptively resulting in complete remission in a patient with pancreatic cancer and partial remission in another patient with gastric cancer.The cytotoxic activities of activated TILs at 3 weeks-incubation was 72 ± 15, 42 ± 26, 27 ± 21 and 25 ± 15% against K562, Daudi, KATO-III and autologous tumor, respectively. The negative selection method, indicated that the killer cells recognizing autologous tumor cells consisted of CD4- or CD8-positive T lymphocytes and CD16- or CD56-positive natural killer cells. The activated TILs could not only lyse cultured tumor cell lines, but also autologous tumor cells.     

金黄色葡萄球菌肠毒素A对H22小鼠移植瘤的抑制作用

旨在探讨金黄色葡萄球菌肠毒素A(SEA)在KM鼠体内的抑瘤效果.建立H22荷瘤小鼠模型,将20只小鼠随机分为对照组(生理盐水)、低剂量组(15 μg/ml)、中剂量组(25 μg/ml)和高剂量组(50 μg/ml),观察肿瘤生长趋势,计算抑瘤率,通过ELISA检测IL-2的含量.结果显示,给药组肿瘤生长趋势均较对照组缓慢;对照组、低剂量组、中剂量组、高剂量组的抑瘤率分别为0,28.9%,34.0%,51.0%(P<0.05);血清中IL-2含量分别为58.9 pg/ml、83.6 pg/ml、91.8 pg/ml、118.1 pg/ml.金黄色葡萄球菌肠毒素A(SEA)可抑制H22肿瘤的生长,并上调IL-2的分泌.     

Effects of granulocyte-colony-stimulating factor and interleukin-2 on ascites formation and the survival time of nude mice bearing human ovarian cancer cells

 The aim of this study was to elucidate the effect of intraperitoneal (i.p.) instillations of granulocyte-colony-stimulating factor (G-CSF) and/or interleukin-2 (IL-2) on ascites formation and the survival time of nude mice with malignant ascites, produced by i.p. inoculation of human ovarian cancer cells. When the nude mice were treated with medium alone, ascites was observed in all mice 28 days after tumor inoculation. When the mice were treated with cis-diamminedichloroplatinum(II) (cisplatin) alone, G-CSF alone or IL-2 alone, it took 35 days for the ascites to form in all mice. When cisplatin was combined with G-CSF or IL-2, one of ten mice did not form ascites during the observation period. Surprisingly, when G-CSF and IL-2 were simultaneously administered, ascites formation was not observed in any mice. Although i.p. treatment with cisplatin alone significantly prolonged the survival time, compared to medium alone, the lytic activity of spleen cells against HRA cells was significantly suppressed. When G-CSF or IL-2 was combined with cisplatin, the suppression by cisplatin was eliminated and subsequently resulted in a prolongation of the survival time. When G-CSF was combined with IL-2, both the peritoneal and splenic macrophages/monocytes were stimulated and the splenic lytic activity was about double that following treatment with G-CSF alone on IL-2 alone, suggesting that complete inhibition of ascites formation results not only from a significant increase of the peritoneal macrophages but also from enhancement of the lytic activity. Two mice, died from dissemination of tumor in the abdominal cavity, but eight mice survived without tumor for more than 90 days. As confirmed by monitoring body weight and hematocrit, G-CSF and IL-2 seemed to have no adverse effect. From these results, we conclude that a combination therapy with G-CSF and IL-2 might be of clinical use for inhibiting large amounts of ascites, which may inhibit therapeutic effects for ovarian cancer patients. Received: 20 May 1996 / Accepted: 19 September 1996     

Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma

Interleukin-36α (IL-36α) has been found to have a prominent role in the pathogenesis of inflammatory disorders; however, little is known about the role of IL-36α in cancer. In this study, we investigated the expression, prognostic value, and the underlying antitumor mechanism of IL-36α in hepatocellular carcinoma (HCC). From immunohistochemistry analysis, IL-36α expression was lower in poorly differentiated HCC cells. In clinicopathological analysis, low IL-36α expression significantly correlated with tumor size, histological differentiation, tumor stage, and vascular invasion, and low intratumoral IL-36α expression had significantly worse overall survival rates and shorter disease-free survival rates. Moreover, intratumoral IL-36α expression was an independent risk factor for overall survival. Consecutive sections were used to detect CD3⁺, CD8⁺, and CD4⁺ tumor-infiltrating lymphocytes (TILs), and we found that high-IL-36α-expressing tumor tissues exhibited a significantly higher proportion of intratumoral CD3⁺ and CD8⁺ TILs, but not CD4⁺ TILs. Our in vitro model confirmed that supernatant from IL-36α-overexpressing human HCC cells had an increased capacity to recruit CD3⁺ and CD8⁺ T cells. Consistently, mouse HCC cells engineered to overexpress IL-36α demonstrated markedly delayed growth in vivo, as well as higher levels of intratumoral CD3⁺ and CD8⁺ TILs, compared with control mice. In vitro chemotaxis analysis also showed that mouse HCC cells overexpressing IL-36α could recruit more number of CD3⁺ and CD8⁺ T cells. These results show that IL-36α expression may play a pivotal role in determining the prognosis of patients with HCC, which we attribute to the activation of adaptive T cell immunity, especially CD8⁺ T cell immune response.